Invivyd Announces Progress in VYD2311 Clinical Program
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 09 2026
0mins
Should l Buy IVVD?
Invivyd announced progress in its REVOLUTION clinical program for VYD2311, an investigational candidate for the prevention of symptomatic COVID-19. The company conducted a pre-specified sample size re-estimation analysis for its Phase 3 DECLARATION study, which triggered an upsizing of approximately 500 additional subjects. Invivyd noted that top-line results are now expected to shift modestly to the third quarter of 2026. Additionally, the company has aligned with the FDA on an initial Pediatric Study Plan, the "DRUMMER" study, to support a potential BLA for VYD2311 in children aged 0-11 years, contingent on the success of the DECLARATION study. "We are thrilled with our progress in the DECLARATION study. Pooled, blinded COVID-19 event accumulation is already robust, and our conservative upsizing algorithm means that we can move to higher confidence in statistical power with very modest additional time. This re-sizing was designed prospectively with our rapid recruitment speed in mind and our desire for the most robust potential dataset. We have an extraordinary, high-value opportunity to change infectious disease medicine near-term," said Marc Elia, chairman of Invivyd.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IVVD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IVVD
Wall Street analysts forecast IVVD stock price to rise
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 1.680
Low
10.00
Averages
10.00
High
10.00
Current: 1.680
Low
10.00
Averages
10.00
High
10.00
About IVVD
Invivyd, Inc. is a biopharmaceutical company. The Company’s proprietary INVYMAB platform approach combines state-of-the-art viral surveillance and predictive modeling with advanced antibody engineering. INVYMAB is designed to facilitate the rapid, serial generation of new monoclonal antibodies (mAbs) to keep pace with evolving viral threats. The Company delivers antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats, such as SARS-CoV-2. Its PEMGARDA (pemivibart) is the Company's first mAb to receive regulatory authorization and is designed to keep pace with SARS-CoV-2 viral evolution. PEMGARDA is used for the pre-exposure prophylaxis (prevention) of COVID-19 in adults and adolescents. Its VYD2311 is optimized for neutralization potency against SARS-CoV-2 lineages such as BA.2.86 and JN.1. The Company also has additional anti-SARS-CoV-2 mAb candidates in discovery and pre-clinical characterization.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Invivyd Chairman to Speak at Health Summit
- Health Summit Speaker: Marc Elia, Chairman of Invivyd's Board, will speak at the POLITICO Health Care Summit on April 21, discussing the role of monoclonal antibodies in viral disease prevention and their importance in improving American health outcomes.
- Gathering of Policymakers: The summit brings together policymakers, industry leaders, and health experts to explore the future of American healthcare, with Elia's insights potentially influencing future health policies and strategies.
- Monoclonal Antibody Potential: Elia emphasizes that monoclonal antibodies can advance medicine beyond the limits of vaccines, which may spark increased investment and research focus on these therapies, impacting the biopharmaceutical landscape.
- Company Overview: Invivyd is dedicated to developing protection against serious viral infectious diseases and has received FDA emergency use authorization, showcasing its innovative capabilities and market potential in the biopharmaceutical sector.
See More
Invivyd Reports Progress in Late-Stage Trial for COVID-19 Therapy VYD2311
- Clinical Trial Progress: Invivyd announced that its pivotal Phase 3 trial, DECLARATION, for the COVID-19 therapy VYD2311 has recorded sufficient clinical events, supporting the statistical power needed to validate the high efficacy targets, indicating the therapy's potential effectiveness.
- Sample Size Adjustment: To enhance the trial's statistical power, Invivyd conducted a sample size re-estimation on April 6, deciding to increase enrollment by nearly 500 additional participants, thereby strengthening the reliability of the trial results.
- Data Release Timeline Shift: Due to variations in recruitment rates, Invivyd has shifted the timeline for sharing DECLARATION's topline data from mid-2026 to Q3 2026, reflecting the company's commitment to data quality.
- Increased Statistical Confidence: Chairman Marc Elia noted that the conservative upsizing algorithm allows for higher confidence in statistical power with very modest additional time, showcasing a positive outlook on the trial results.
See More
Invivyd Announces Progress in COVID-19 Study and New Measles Antibody Candidate
- Study Progress: The DECLARATION study for VYD2311 has accumulated approximately 50% of COVID-19 events, providing sufficient statistical power to support anticipated high efficacy levels, which is expected to offer robust data for future vaccine development.
- Sample Size Adjustment: A sample size re-estimation was conducted when 1,500 patients reached Day 45, increasing enrollment by about 500 subjects, with results now expected to shift from mid-2026 to Q3 2026, enhancing confidence in study outcomes.
- Pediatric Study Plan: Invivyd has aligned with the U.S. FDA on an initial Pediatric Study Plan for VYD2311, aimed at supporting immunobridging and safety studies for children aged 0-11, with the DRUMMER clinical trial set to commence if the DECLARATION study is successful.
- New Antibody Candidate: Invivyd announced the discovery of VMS063, a novel, highly potent, half-life-extended monoclonal antibody targeting the measles virus fusion protein, expected to provide new treatment and prevention options for high-risk populations.
See More
Invivyd Launches National Antibody Education Campaign
- Campaign Launch: Invivyd has initiated the 'Antibodies for Any Body' national education campaign in New Haven, aiming to enhance public understanding of antibodies and their critical role in immune health, particularly as infectious disease prevention gains national importance.
- Interactive Assessment Tool: The newly launched website, AntibodiesforAnyBody.com, offers clear information on immune health and features an interactive wellness assessment tool designed to help individuals understand how their daily habits can influence antibody production and function, thereby increasing health awareness.
- Celebrity Partnership: The campaign collaborates with ski champion Lindsey Vonn, leveraging her influence and health philosophy to emphasize the importance of antibodies in maintaining health, aiming to inspire the public to adopt proactive health habits through her personal story.
- Long-term Strategic Goals: This initiative not only serves to educate the public about antibodies but also reflects Invivyd's commitment to enhancing health awareness, which is expected to boost the company's brand recognition and market impact in the biopharmaceutical sector.
See More
Invivyd Grants Stock Options to New Employees
- Stock Option Grant: On April 1, 2026, Invivyd granted a total of 1,083,750 stock options to 16 newly hired non-executive employees as a material inducement for their employment, reflecting the company's commitment to attracting talent.
- Exercise Price Setting: The options have an exercise price of $1.33 per share, which matches the closing price of Invivyd's common stock on the grant date, facilitating potential capital appreciation for employees in the future.
- Vesting Arrangement: The options vest over four years, with 25% vesting on the first anniversary of the employee's start date and the remaining shares vesting in equal monthly installments, ensuring employees remain with the company to realize full benefits.
- Long-term Incentive Mechanism: With a 10-year term, the options are subject to the terms of the Invivyd 2026 Inducement Plan, aiming to enhance employee loyalty and motivation through long-term incentives, thereby driving sustainable business growth.
See More
BETA Technologies Reports Disappointing Q4 Results
- Earnings Miss: BETA Technologies reported a Q4 loss of $2.02 per share, significantly worse than the analyst consensus estimate of a loss of $0.84, indicating substantial challenges in profitability that could undermine investor confidence.
- Sales Beat: Despite the significant losses, the company achieved quarterly sales of $11.133 million, surpassing the analyst consensus of $7.859 million, suggesting some resilience in market demand that could lay the groundwork for future growth.
- Stock Reaction: In pre-market trading, BETA's shares fell 3.1% to $18.67, reflecting a negative investor response to the earnings report, which may lead to increased liquidity pressure in the short term.
- Market Sentiment: The overall market sentiment is bearish, with Dow futures down over 1%, indicating investor concerns about the economic outlook, which could further impact BETA Technologies and other related stocks.
See More
Invivyd Chairman to Speak at Health Summit
- Health Summit Speaker: Marc Elia, Chairman of Invivyd's Board, will speak at the POLITICO Health Care Summit on April 21, discussing the role of monoclonal antibodies in viral disease prevention and their importance in improving American health outcomes.
- Gathering of Policymakers: The summit brings together policymakers, industry leaders, and health experts to explore the future of American healthcare, with Elia's insights potentially influencing future health policies and strategies.
- Monoclonal Antibody Potential: Elia emphasizes that monoclonal antibodies can advance medicine beyond the limits of vaccines, which may spark increased investment and research focus on these therapies, impacting the biopharmaceutical landscape.
- Company Overview: Invivyd is dedicated to developing protection against serious viral infectious diseases and has received FDA emergency use authorization, showcasing its innovative capabilities and market potential in the biopharmaceutical sector.
See More
Invivyd Reports Progress in Late-Stage Trial for COVID-19 Therapy VYD2311
- Clinical Trial Progress: Invivyd announced that its pivotal Phase 3 trial, DECLARATION, for the COVID-19 therapy VYD2311 has recorded sufficient clinical events, supporting the statistical power needed to validate the high efficacy targets, indicating the therapy's potential effectiveness.
- Sample Size Adjustment: To enhance the trial's statistical power, Invivyd conducted a sample size re-estimation on April 6, deciding to increase enrollment by nearly 500 additional participants, thereby strengthening the reliability of the trial results.
- Data Release Timeline Shift: Due to variations in recruitment rates, Invivyd has shifted the timeline for sharing DECLARATION's topline data from mid-2026 to Q3 2026, reflecting the company's commitment to data quality.
- Increased Statistical Confidence: Chairman Marc Elia noted that the conservative upsizing algorithm allows for higher confidence in statistical power with very modest additional time, showcasing a positive outlook on the trial results.
See More
Invivyd Announces Progress in COVID-19 Study and New Measles Antibody Candidate
- Study Progress: The DECLARATION study for VYD2311 has accumulated approximately 50% of COVID-19 events, providing sufficient statistical power to support anticipated high efficacy levels, which is expected to offer robust data for future vaccine development.
- Sample Size Adjustment: A sample size re-estimation was conducted when 1,500 patients reached Day 45, increasing enrollment by about 500 subjects, with results now expected to shift from mid-2026 to Q3 2026, enhancing confidence in study outcomes.
- Pediatric Study Plan: Invivyd has aligned with the U.S. FDA on an initial Pediatric Study Plan for VYD2311, aimed at supporting immunobridging and safety studies for children aged 0-11, with the DRUMMER clinical trial set to commence if the DECLARATION study is successful.
- New Antibody Candidate: Invivyd announced the discovery of VMS063, a novel, highly potent, half-life-extended monoclonal antibody targeting the measles virus fusion protein, expected to provide new treatment and prevention options for high-risk populations.
See More
Invivyd Launches National Antibody Education Campaign
- Campaign Launch: Invivyd has initiated the 'Antibodies for Any Body' national education campaign in New Haven, aiming to enhance public understanding of antibodies and their critical role in immune health, particularly as infectious disease prevention gains national importance.
- Interactive Assessment Tool: The newly launched website, AntibodiesforAnyBody.com, offers clear information on immune health and features an interactive wellness assessment tool designed to help individuals understand how their daily habits can influence antibody production and function, thereby increasing health awareness.
- Celebrity Partnership: The campaign collaborates with ski champion Lindsey Vonn, leveraging her influence and health philosophy to emphasize the importance of antibodies in maintaining health, aiming to inspire the public to adopt proactive health habits through her personal story.
- Long-term Strategic Goals: This initiative not only serves to educate the public about antibodies but also reflects Invivyd's commitment to enhancing health awareness, which is expected to boost the company's brand recognition and market impact in the biopharmaceutical sector.
See More
Invivyd Grants Stock Options to New Employees
- Stock Option Grant: On April 1, 2026, Invivyd granted a total of 1,083,750 stock options to 16 newly hired non-executive employees as a material inducement for their employment, reflecting the company's commitment to attracting talent.
- Exercise Price Setting: The options have an exercise price of $1.33 per share, which matches the closing price of Invivyd's common stock on the grant date, facilitating potential capital appreciation for employees in the future.
- Vesting Arrangement: The options vest over four years, with 25% vesting on the first anniversary of the employee's start date and the remaining shares vesting in equal monthly installments, ensuring employees remain with the company to realize full benefits.
- Long-term Incentive Mechanism: With a 10-year term, the options are subject to the terms of the Invivyd 2026 Inducement Plan, aiming to enhance employee loyalty and motivation through long-term incentives, thereby driving sustainable business growth.
See More
BETA Technologies Reports Disappointing Q4 Results
- Earnings Miss: BETA Technologies reported a Q4 loss of $2.02 per share, significantly worse than the analyst consensus estimate of a loss of $0.84, indicating substantial challenges in profitability that could undermine investor confidence.
- Sales Beat: Despite the significant losses, the company achieved quarterly sales of $11.133 million, surpassing the analyst consensus of $7.859 million, suggesting some resilience in market demand that could lay the groundwork for future growth.
- Stock Reaction: In pre-market trading, BETA's shares fell 3.1% to $18.67, reflecting a negative investor response to the earnings report, which may lead to increased liquidity pressure in the short term.
- Market Sentiment: The overall market sentiment is bearish, with Dow futures down over 1%, indicating investor concerns about the economic outlook, which could further impact BETA Technologies and other related stocks.
See More
